{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:32:06Z","timestamp":1790526726205,"version":"4.1.0"},"reference-count":227,"publisher":"Wiley","issue":"S7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2526,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,10,1]]},"DOI":"10.1002\/cncr.23655","type":"journal-article","created":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T19:17:12Z","timestamp":1267557432000},"page":"1933-1952","source":"Crossref","is-referenced-by-count":70,"special_numbering":"supplement 7","title":["Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years"],"prefix":"10.1002","volume":"113","author":[{"given":"Hagop","family":"Kantarjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elihu","family":"Estey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil J.","family":"Freireich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"10.1002\/cncr.23655-BIB1","first-page":"2573","article-title":"First continuous infusion (12) hour Ara-C 14 patients, 6 CRs and 2 PRs. Therapy for acute granulocytic leukemia","volume":"27","author":"Freireich","year":"1967","journal-title":"Cancer Res."},{"key":"10.1002\/cncr.23655-BIB2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0140-6736(69)91296-3","article-title":"Daunorubicin in the treatment of acute myeloblastic leukemia","volume":"1","author":"Boiron","year":"1969","journal-title":"Lancet."},{"key":"10.1002\/cncr.23655-BIB3","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1002\/cncr.23000","article-title":"Progress in the treatment of acute myeloid leukemia","volume":"110","author":"Ravandi","year":"2007","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive post remission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB5","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","article-title":"A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study","volume":"88","author":"Weick","year":"1996","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB6","first-page":"4116","article-title":"Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group","volume":"93","author":"Buchner","year":"1999","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB7","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V87.5.1710.1710","article-title":"A randomized study of high-dose cytarabine in induction in acute myeloid leukemia","volume":"87","author":"Bishop","year":"1996","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB8","first-page":"4173","article-title":"Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype","volume":"58","author":"Bloomfield","year":"1998","journal-title":"Cancer Res."},{"key":"10.1002\/cncr.23655-BIB9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.21543","article-title":"High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of 3 randomized trials","volume":"107","author":"Kern","year":"2006","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB10","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.V77.8.1666.1666","article-title":"Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia","volume":"77","author":"Berman","year":"1991","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood.V79.2.313.313","article-title":"Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia","volume":"79","author":"Wiernik","year":"1992","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB12","first-page":"102","article-title":"Daunorubicin (DNR) vs mitoxantrone (MTZ) vs idarubicin (IDA) administered during induction and consolidation in acute myelogenous leukemia (AML) followed by autologous or allogeneic stem transplantation (SCT): results of the EORTC-GIMEMA","author":"Vignetti","year":"2003","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB13","first-page":"110","article-title":"Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 days in AML pts aged 50 to 70 and of maintenance with interleukin 2. Final analysis of the Alfa 9801 Study","author":"Pautas","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB14","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood.V93.8.2478","article-title":"Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin \u00b1 all-trans retinoic acid \u00b1 granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome","volume":"93","author":"Estey","year":"1999","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB15","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1365-2141.2003.04702.x","article-title":"Increased remissions from 1 course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study","volume":"123","author":"Juliusson","year":"2003","journal-title":"Br J Haematol."},{"key":"10.1002\/cncr.23655-BIB16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V75.1.27.27","article-title":"Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group","volume":"75","author":"Bishop","year":"1990","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB17","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/cncr.21699","article-title":"Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB18","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood.V99.3.759","article-title":"Acute promyelocytic leukemia: evolving therapeutic strategies","volume":"99","author":"Tallman","year":"2002","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB19","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-02-0632","article-title":"All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol","volume":"100","author":"Tallman","year":"2002","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB20","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2005-08-3532","article-title":"Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity","volume":"107","author":"Mathews","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB21","first-page":"3015","article-title":"A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML\/RAR\u03b1-positive acute promyelocytic leukemia","volume":"94","author":"Sanz","year":"1999","journal-title":"Blood."},{"issue":"18S","key":"10.1002\/cncr.23655-BIB22","article-title":"Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. 2007 ASCO Annual Meeting Proceedings","volume":"25","author":"Powell","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB23","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1182\/blood-2004-04-1550","article-title":"Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia","volume":"104","author":"Lo-Coco","year":"2004","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB24","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2005-10-4006","article-title":"Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia","volume":"107","author":"Estey","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB25","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2005.15.610","article-title":"Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study","volume":"23","author":"Marcucci","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB26","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.2004.07.012","article-title":"Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv (16) (p13q22) or t (16;16) (p13;q22): results from CALGB 8461","volume":"22","author":"Byrd","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB27","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB28","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB29","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood.V98.5.1302","article-title":"Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Goldstone","year":"2001","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB30","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archinte.162.14.1597","article-title":"The outcomes and costs of acute myeloid leukemia among the elderly","volume":"162","author":"Menzin","year":"2002","journal-title":"Arch Intern Med."},{"key":"10.1002\/cncr.23655-BIB31","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB32","first-page":"106","article-title":"Clofarabine and clofarabine plus low dose cytarabine (ara-C) as induction acute myeloid leukemia (AML)","author":"Faderl","year":"2005","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB33","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.leukres.2006.02.019","article-title":"A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia","volume":"30","author":"Giles","year":"2006","journal-title":"Leuk Res."},{"key":"10.1002\/cncr.23655-BIB34","first-page":"110","article-title":"Continued low-dose decitabine (DAC) is an active first-line treatment in all cytogenetic subgroups of older AML patients: results of the FR00331 multicenter phase II study","author":"Lubbert","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB35","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB36","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cncr.22502","article-title":"Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB37","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB38","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB39","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB40","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB41","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"10.1002\/cncr.23655-BIB42","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","article-title":"Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia","volume":"103","author":"Smith","year":"2004","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB44","doi-asserted-by":"crossref","first-page":"121a","DOI":"10.1182\/blood.V106.11.403.403","article-title":"A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition","volume":"106","author":"Levis","year":"2005","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB45","doi-asserted-by":"crossref","first-page":"50a","DOI":"10.1182\/blood.V108.11.157.157","article-title":"Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML","volume":"108","author":"Stone","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB46","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1182\/blood-2005-05-2164","article-title":"Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations","volume":"106","author":"Dohner","year":"2005","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB47","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2005-06-2248","article-title":"Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype","volume":"106","author":"Schnittger","year":"2005","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB48","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1200\/JCO.2002.09.088","article-title":"Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm","volume":"20","author":"Dohner","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB49","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1182\/blood-2002-03-0990","article-title":"Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)","volume":"100","author":"Preudhomme","year":"2002","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB50","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1200\/JCO.2004.06.060","article-title":"CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations","volume":"22","author":"Frohling","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB51","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2005.01.6253","article-title":"BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications","volume":"24","author":"Baldus","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB52","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMoa031046","article-title":"Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia","volume":"350","author":"Bullinger","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB53","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJMoa040465","article-title":"Prognostically useful gene-expression profiles in acute myeloid leukemia","volume":"350","author":"Valk","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB54","doi-asserted-by":"crossref","first-page":"8a","DOI":"10.1182\/blood.V108.11.13.13","article-title":"The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial","volume":"108","author":"Burnett","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB55","doi-asserted-by":"crossref","first-page":"7107","DOI":"10.1158\/1078-0432.CCR-07-1193","article-title":"Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome","volume":"13","author":"Grovdal","year":"2007","journal-title":"Clin Cancer Res."},{"key":"10.1002\/cncr.23655-BIB56","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/cncr.11935","article-title":"New agents in acute myeloid leukemia and other myeloid disorders","volume":"100","author":"Ravandi","year":"2004","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJM199501263320403","article-title":"Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups","volume":"332","author":"Zittoun","year":"1995","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB58","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199812033392301","article-title":"Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission","volume":"339","author":"Cassileth","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB59","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.1994.12.2.262","article-title":"Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia","volume":"12","author":"Archimbaud","year":"2994","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB60","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2003-03-0855","article-title":"Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years","volume":"102","author":"Wong","year":"2003","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB61","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB62","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra023001","article-title":"Acute lymphoblastic leukemia","volume":"350","author":"Pui","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB63","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB64","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/cncr.11664","article-title":"The biology and therapy of adult acute lymphoblastic leukemia","volume":"98","author":"Faderl","year":"2003","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB65","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0889-8588(05)70189-1","article-title":"The Medical Research Council trials in adult acute lymphocytic leukemia","volume":"14","author":"Durrant","year":"2000","journal-title":"Hematol Oncol Clin North Am."},{"key":"10.1002\/cncr.23655-BIB66","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0889-8588(05)70190-8","article-title":"Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation: a follow-up report of the French Protocol LALA 87","volume":"14","author":"Thiebaut","year":"2000","journal-title":"Hematol Oncol Clin North Am."},{"key":"10.1002\/cncr.23655-BIB67","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0889-8588(05)70188-X","article-title":"Treatment of adult ALL according to protocols of the German Multicenter study group for adult ALL (GMALL)","volume":"14","author":"Gokbuget","year":"2000","journal-title":"Hematol Oncol Clin North Am."},{"key":"10.1002\/cncr.23655-BIB68","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0889-8588(05)70191-X","article-title":"Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B","volume":"14","author":"Larson","year":"2000","journal-title":"Hematol Oncol Clin North Am."},{"key":"10.1002\/cncr.23655-BIB69","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/blood.V78.11.2814.2814","article-title":"Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report","volume":"78","author":"Linker","year":"1991","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB70","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB71","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2002-08-2454","article-title":"Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group","volume":"101","author":"Bostrom","year":"2003","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB72","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2005.05509.x","article-title":"Benefit of dexamethasone compared with prednisone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL 97 randomized trial","volume":"129","author":"Mitchell","year":"2005","journal-title":"Br J Haematol."},{"key":"10.1002\/cncr.23655-BIB73","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1046\/j.1365-2141.2002.03685.x","article-title":"High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia","volume":"118","author":"Hallbook","year":"2002","journal-title":"Br J Haematol."},{"key":"10.1002\/cncr.23655-BIB74","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-0","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB75","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy","volume":"338","author":"Nachman","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB76","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose of L-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB77","first-page":"3310","article-title":"Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90","volume":"95","author":"Schrappe","year":"2000","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB78","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1200\/JCO.2000.18.7.1508","article-title":"Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood","volume":"18","author":"Toyoda","year":"2000","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB79","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1200\/JCO.2003.10.032","article-title":"Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia","volume":"21","author":"Pui","year":"2003","journal-title":"JClin Oncol."},{"key":"10.1002\/cncr.23655-BIB80","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood.V86.6.2091.bloodjournal8662091","article-title":"The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia","volume":"86","author":"Cortes","year":"1995","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB81","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2004-07-2922","article-title":"A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol","volume":"105","author":"Mancini","year":"2005","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB82","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1200\/JCO.2005.05.047","article-title":"Molecular genetics of acute lymphoblastic leukemia","volume":"23","author":"Armstrong","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB83","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Gleissner","year":"2002","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB84","first-page":"467a","article-title":"Outcome of adolescents and young adults with ALL: a comparison of Children's Cancer Group (CCG) and Cancer and Leukemia Group B (CALGB) regimens","volume":"96","author":"Stock","year":"2000","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB85","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB86","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403538","article-title":"Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands","volume":"18","author":"de Bont","year":"2004","journal-title":"Leukemia."},{"key":"10.1002\/cncr.23655-BIB87","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/cncr.22189","article-title":"Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol","volume":"107","author":"Hallook","year":"2006","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB88","first-page":"110","article-title":"A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia","author":"DeAngelo","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB89","first-page":"110","article-title":"Improved outcome of adult acute lymphoblastic leukemia treated with a pediatric protocol: results of a pilot study","author":"Haiat","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB90","first-page":"108","article-title":"Towards a pediatric approach in adults with acute lymphoblastic leukemia (ALL): the GRAALL-2003 Study","author":"Huguet","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB91","doi-asserted-by":"crossref","first-page":"428","DOI":"10.7326\/0003-4819-123-6-199509150-00006","article-title":"Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation","volume":"123","author":"Zhang","year":"1995","journal-title":"Ann Intern Med."},{"key":"10.1002\/cncr.23655-BIB92","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.V86.4.1619.bloodjournal8641619","article-title":"Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group","volume":"86","author":"Attal","year":"1995","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB93","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lyphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogenic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993)","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB94","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB95","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB96","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB97","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","article-title":"Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study","volume":"109","author":"de Labarthe","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB98","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB99","first-page":"110","article-title":"Does imatinib change the outcome in Philadelphia chromosome positive acute lymphoblastic leukaemia in adults? Data from the UK ALL XII\/ECOG2993 study","author":"Fielding","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB100","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","article-title":"Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB101","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","article-title":"Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies","volume":"23","author":"Kurtzberg","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB102","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB103","first-page":"3983","article-title":"Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience","volume":"93","author":"Wetzler","year":"1999","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB104","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UK ALL XII\/Eastern Cooperative Oncology Group (ECOG) 2993 Trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB105","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa033513","article-title":"Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment","volume":"351","author":"Holleman","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB106","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2005.03.002","article-title":"Identification of genes associated with chemotherapy cross resistance and treatment response in childhood acute lymphoblastic leukemia","volume":"7","author":"Lugthart","year":"2005","journal-title":"Cancer Cell."},{"key":"10.1002\/cncr.23655-BIB107","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1535-6108(02)00032-6","article-title":"Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling","volume":"1","author":"Yeoh","year":"2002","journal-title":"Cancer Cell."},{"key":"10.1002\/cncr.23655-BIB108","doi-asserted-by":"crossref","first-page":"521a","DOI":"10.1182\/blood.V106.11.1831.1831","article-title":"Update of the modified hyper-CVAD regimen with or without rituximab in newly diagnosed adult acute lymphocytic leukemia (ALL)","volume":"106","author":"Thomas","year":"2005","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB109","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB110","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.21005","article-title":"The role of clofarabine in hematologic and solid malignancies-development of a next-generation nucleoside analog","volume":"103","author":"Faderl","year":"2005","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB111","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cncr.21595","article-title":"Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB112","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB113","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","article-title":"Pharmacodynamics and safety of intravenous pegasparginase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia","volume":"109","author":"Douer","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB114","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2006-08-043646","article-title":"Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia","volume":"109","author":"Jabbour","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB115","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cncr.21901","article-title":"Activity of alemtuzumab in patients with CD52-positive acute leukemia","volume":"106","author":"Tibes","year":"2006","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB116","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","article-title":"Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB117","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/cncr.22661","article-title":"Current and emerging treatment options in chronic myeloid leukemia","volume":"109","author":"Jabbour","year":"2007","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB118","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia-advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB119","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7326\/0003-4819-122-4-199502150-00003","article-title":"Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-\u03b1","volume":"122","author":"Kantarjian","year":"1995","journal-title":"Ann Intern Med."},{"key":"10.1002\/cncr.23655-BIB120","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","article-title":"Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group","volume":"89","year":"1997","unstructured":"[No authors listed] Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst. 1997; 89: 1616-1620.","journal-title":"J Natl Cancer Inst."},{"key":"10.1002\/cncr.23655-BIB121","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-\u03b1-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB122","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med."},{"key":"10.1002\/cncr.23655-BIB123","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4065\/81.7.973","article-title":"Chronic myeloid leukemia diagnosis and treatment","volume":"81","author":"Quintas-Cardama","year":"2006","journal-title":"Mayo Clin Proc."},{"key":"10.1002\/cncr.23655-BIB124","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB125","first-page":"908","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"12","author":"Druker","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB126","first-page":"2177","article-title":"Imatinib mesylate for Philadelphia-chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-\u03b1: follow-up results","volume":"8","author":"Kantarjian","year":"2002","journal-title":"Clin Can Res."},{"key":"10.1002\/cncr.23655-BIB127","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-\u03b1-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB128","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-\u03b1 plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB129","first-page":"110","article-title":"IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","author":"Hochhaus","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB130","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB131","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB132","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2003-06-2042","article-title":"Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses","volume":"102","author":"Marin","year":"2003","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB133","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate","volume":"11","author":"Cortes","year":"2005","journal-title":"Clin Cancer Res."},{"key":"10.1002\/cncr.23655-BIB134","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","article-title":"BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res."},{"key":"10.1002\/cncr.23655-BIB135","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB136","first-page":"31a","article-title":"Trial of higher dose imatinib with selective intensification in newly diagnosed CML patients in chronic phase","volume":"102","author":"Hughes","year":"2003","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB137","first-page":"24","article-title":"High-dose imatinib mesylate treatment in patients (pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up","author":"Aoki","year":"2006","journal-title":"Proc Am Soc Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB138","first-page":"108","article-title":"Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib; an analysis of IRIS study data","author":"Larson","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB139","first-page":"110","article-title":"Lower dose of imatinib provides outcomes similar to the standard dose imatinib in Japanese patients with early chronic-phase CML: the interim analyses of JALSG CML202 study","author":"Ohnishi","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"1007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB141","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-01-070045","article-title":"Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB142","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/cncr.22936","article-title":"The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells","volume":"110","author":"Deininger","year":"2007","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB143","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB144","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia."},{"key":"10.1002\/cncr.23655-BIB145","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia."},{"key":"10.1002\/cncr.23655-BIB146","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/cncr.22569","article-title":"Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB147","first-page":"110","article-title":"Impact of prior therapy with imatinib mesylate on the outcome of hematopoietic cell transplantation (HCT) for chronic myeloid leukemia (CML)","author":"Lee","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB148","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB149","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB150","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB151","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB152","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB153","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB154","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB155","first-page":"110","article-title":"Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML)","author":"Cortes","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB156","first-page":"110","article-title":"A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors","author":"Kantarjian","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB157","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase II trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB158","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB159","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB160","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB161","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2002-07-1973","article-title":"Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB162","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","article-title":"Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate","volume":"23","author":"Issa","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB163","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/cncr.20975","article-title":"Phase I\/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib","volume":"103","author":"Marin","year":"2005","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB164","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210BCR\/ABL gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science."},{"key":"10.1002\/cncr.23655-BIB165","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with V-ABL and BCR\/ABL","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1002\/cncr.23655-BIB166","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB167","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","article-title":"Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods","volume":"111","author":"Kantarjian","year":"2008","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB168","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy","volume":"92","author":"Keating","year":"1998","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB169","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB170","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB171","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomized controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet."},{"key":"10.1002\/cncr.23655-BIB172","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(96)91681-5","article-title":"Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL","volume":"347","author":"Johnson","year":"1996","journal-title":"Lancet."},{"key":"10.1002\/cncr.23655-BIB173","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB174","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB175","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB176","first-page":"709","article-title":"Inhibition of interleukin 10 by rituximab results in down-regulation of BCL-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis","volume":"7","author":"Alas","year":"2001","journal-title":"Clin Cancer Res."},{"key":"10.1002\/cncr.23655-BIB177","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1046\/j.1365-2141.2001.03014.x","article-title":"Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone","volume":"114","author":"Di Gaetano","year":"2001","journal-title":"Br J Haematol."},{"key":"10.1002\/cncr.23655-BIB178","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB179","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.exphem.2003.09.021","article-title":"Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival","volume":"32","author":"Khouri","year":"2004","journal-title":"Exp Hematol."},{"key":"10.1002\/cncr.23655-BIB181","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB182","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB183","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB184","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood-2005-12-051458","article-title":"Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia","volume":"109","author":"Wierda","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB185","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD 38 expression as novel progmostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damie","year":"1999","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB186","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB187","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB188","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa040857","article-title":"ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia","volume":"351","author":"Rassenti","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB189","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB190","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 Gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB191","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1182\/blood.V79.5.1111.1111","article-title":"Treatment of hairy cell leukemia","volume":"79","author":"Saven","year":"1992","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB192","first-page":"2981","article-title":"Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostastin","volume":"96","author":"Flinn","year":"2000","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB193","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1200\/JCO.2003.05.093","article-title":"Extended follow-up of patients with hairy cell leukemia after treatment with cladribine","volume":"21","author":"Goodman","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB194","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","article-title":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study","volume":"13","author":"Grever","year":"1995","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB195","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1182\/blood-2005-11-4590","article-title":"Eradication of minimal residual disease in hairy cell leukemia","volume":"107","author":"Ravandi","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB196","first-page":"2144","volume-title":"Cancer: Principles and Practice of Oncology","author":"Faderl","year":"2005"},{"key":"10.1002\/cncr.23655-BIB197","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/cncr.20381","article-title":"Novel therapies for myelodysplastic syndromes","volume":"101","author":"Faderl","year":"2004","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB198","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Heamatol."},{"key":"10.1002\/cncr.23655-BIB199","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1977","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB200","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB201","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision-making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB202","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood.V90.7.2843","article-title":"Application of the international scoring system for myelodysplasia to M. D. Anderson patients","volume":"90","author":"Estey","year":"1997","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB203","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB204","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcome in myelodysplastic syndrome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB205","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB206","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/cncr.22508","article-title":"Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB207","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cncr.22376","article-title":"Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB208","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23655-BIB209","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB210","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood-2004-10-3872","article-title":"Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF","volume":"106","author":"Jadersten","year":"2005","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB211","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"J\u00e4dersten","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB212","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/sj.leu.2404747","article-title":"Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin","volume":"21","author":"Lim","year":"2007","journal-title":"Leukemia."},{"key":"10.1002\/cncr.23655-BIB213","doi-asserted-by":"crossref","first-page":"781a","DOI":"10.1182\/blood.V108.11.2656.2656","article-title":"Retrospective survey of Japanese patients with transfusion-dependent myelodysplastic syndromes and aplastic anemia highlights the negative impact of iron overload on morbidity\/mortality","volume":"108","author":"Takatoku","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB214","doi-asserted-by":"crossref","first-page":"78a","DOI":"10.1182\/blood.V108.11.249.249","article-title":"Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy","volume":"108","author":"Leitch","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB215","doi-asserted-by":"crossref","first-page":"78a","DOI":"10.1182\/blood.V110.11.249.249","article-title":"Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. a prospective analysis by the GFM","volume":"110","author":"Rose","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB216","doi-asserted-by":"crossref","first-page":"246a","DOI":"10.1182\/blood.V110.11.819.819","article-title":"Results of the initial treatment phase of a study of three alternative dosing schedules of azacitidine (Vidaza\u00ae) in patients with myelodysplastic syndromes (MDS)","volume":"110","author":"Lyons","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB217","doi-asserted-by":"crossref","first-page":"245a","DOI":"10.1182\/blood.V110.11.817.817","article-title":"Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional cure regimens (CCR); results of the AZA-001 phase III study","volume":"110","author":"Fenaux","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB218","doi-asserted-by":"crossref","first-page":"292b","DOI":"10.1182\/blood.V108.11.4868.4868","article-title":"G-CSF increases hematological response among patients with myelodysplasia treated with azacitidine","volume":"108","author":"Rossetti","year":"2006","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB219","doi-asserted-by":"crossref","first-page":"420a","DOI":"10.1182\/blood.V110.11.1452.1452","article-title":"Therapy of myelodysplastic syndrome (MDS) with azacitidine given in combination with etanercept: a phase II study","volume":"110","author":"Holsinger","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB220","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/1097-0142(20011015)92:8<1999::AID-CNCR1538>3.0.CO;2-B","article-title":"Chemotherapy in high-risk myelodysplastic syndrome-Covariate-adjusted comparison of five regimens","volume":"92","author":"Beran","year":"2001","journal-title":"Cancer."},{"key":"10.1002\/cncr.23655-BIB221","first-page":"1997","article-title":"Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia","volume":"100","author":"Sierra","year":"2002","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB222","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB223","doi-asserted-by":"crossref","first-page":"77a","DOI":"10.1182\/blood.V110.11.247.247","article-title":"Multivariate evaluation of the prognostic and therapeutic relevance of cytogenetics in a merged European-American cohort of 3860 patients with MDS","volume":"110","author":"Haase","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB224","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q\u2212 syndrome gene by RNA interference screen","volume":"451","author":"Ebert","year":"2008","journal-title":"Nature."},{"key":"10.1002\/cncr.23655-BIB225","doi-asserted-by":"crossref","first-page":"421a","DOI":"10.1182\/blood.V110.11.1455.1455","article-title":"Results of an exploratory study of oral (po) and intravenous (iv) clofarabine in patients with myelodysplastic syndrome","volume":"110","author":"Faderl","year":"2007","journal-title":"Blood."},{"key":"10.1002\/cncr.23655-BIB226","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2005.03.9503","article-title":"Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study","volume":"24","author":"Vey","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23655-BIB227","first-page":"110","article-title":"Phase 1\/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): update including extended treatment","author":"Kantarjian","year":"2007","journal-title":"Blood."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23655","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/cncr.23655\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T04:07:06Z","timestamp":1625198826000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,1]]},"references-count":227,"journal-issue":{"issue":"S7","published-print":{"date-parts":[[2008,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/cncr.23655","relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,1]]}}}